Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_assertion type Assertion NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_head.
- NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_assertion description "[Although the previous standard of care in patients with EGFR-mutated NSCLC that progressed on initial TKI therapy was chemotherapy, third-generation EGFR TKIs have now been developed and have yielded promising results for this population of patients with NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_provenance.
- NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_assertion evidence source_evidence_literature NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_provenance.
- NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_assertion SIO_000772 25521095 NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_provenance.
- NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_assertion wasDerivedFrom befree-2016 NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_provenance.
- NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_assertion wasGeneratedBy ECO_0000203 NP1249148.RA37kde9WP0zvGTaRSC0DyYZ_jZLrV6i0cZVRl8bVCszg130_provenance.